US$0.94+22.5%11月13日 收盘
The latest quarter (ended 2026年9月30日) is from Cerenome’s earnings press release of 2026年11月13日. It will be replaced by the official quarterly report (10-Q) once Cerenome files it.
Just reported
From Cerenome, Inc.'s results release of 2026年11月13日. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
US$722K
-48% y/y
+76% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$722K | US$1.4M | -48.32% |
| 利润 | -US$8.7M | -US$4.4M | -95.73% |
| 自由现金流 | -US$7.7M | -US$2.6M | -200.00% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
Cerenome, Inc. reported on 2026年11月13日. We are fetching the call transcript; its summary follows once the transcript is in.
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
(LM) Leptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies.
公司自己的描述，取自公告末尾。
The quote, the company description and the latest quarter come from Cerenome’s earnings press release (an Item 2.02 8-K) filed 2026年11月13日. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. 在 EDGAR 上阅读公告 股价已按拆股和分红复权。